Novartis: melanoma treatment approved in Europe
(CercleFinance.com) - Novartis' combination of Tafinlar and Mekinist has been approved for the treatment of stage III melanoma patients in the European Union, the Swiss drugmaker said on Wednesday.
The European Commission has approved Tafinlar, in combination with Mekinist, for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection, it said.
The approval is based on results from a Phase III study, which enrolled more than 870 patients, showing that the therapy reduced the risk of disease recurrence or death by 53% vs. placebo.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The European Commission has approved Tafinlar, in combination with Mekinist, for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection, it said.
The approval is based on results from a Phase III study, which enrolled more than 870 patients, showing that the therapy reduced the risk of disease recurrence or death by 53% vs. placebo.
Copyright (c) 2018 CercleFinance.com. All rights reserved.